Sihuan Pharmaceuticals hopes to raise up to $741m through its Hong Kong public offering, according to Reuters.

China’s largest cardio-cerebral vascular drug manufacturer is selling 1.25 billion new shares, equivalent to 25% of its share capital.

The company has also signed up six investors, including CCB International and China Life Insurance, for a combined $190m worth of shares.

Investment in Chinese medical firms has grown recently, a result of Beijing’s promises to create a national healthcare system coupled with the sector’s strong market momentum and ability to produce a quick profit for investors.

Sihuan markets its products, including cardio-cerebral vascular, metabolic and nervous system medications, through a network covering approximately 10,000 hospitals and medical institutions across China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.